You just read:

According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients

News provided by

BioTrends Research Group

Dec 19, 2013, 08:00 ET